Overview of Centyl K

Quick Facts

Property	Description
Active Ingredient(s)	Bendroflumethiazide, Potassium Chloride
Form	Modified-release film-coated oral tablet
Pharmacological Class	Thiazide Diuretic and Electrolyte Replenisher
General Purpose	Fluid reduction and potassium balance maintenance
Origin	Synthetic (Bendroflumethiazide) and Mineral (Potassium Chloride)

What is Centyl K and Its Pharmacological Identity?

Centyl K is a prescription-only combination medicinal product that is structurally defined by its two distinct active pharmaceutical ingredients: Bendroflumethiazide and Potassium Chloride. It is officially classified as a Thiazide Diuretic and an Electrolyte Replenisher.

The formulation is clinically recognized for integrating the therapeutic action of fluid reduction with necessary electrolyte support. Bendroflumethiazide is a synthetic compound that falls under the diuretic class, while Potassium Chloride is a mineral salt. This unique fixed-dose combination product is designed for adult patients requiring sustained diuretic therapy, where preventing electrolyte disturbance is a crucial design factor.

Composition and Physical Form of Centyl K

Centyl K is administered via the oral route of administration as a distinctive modified-release film-coated tablet. This structure is defined by the combined presence of the two active ingredients embedded within solid pharmaceutical excipients.

This modified-release tablet is engineered to provide a controlled delivery profile, differentiating it from immediate-release formulations. The design allows the components to be absorbed gradually, which is particularly relevant for the Potassium Chloride component to ensure a sustained release and support consistent Potassium Balance Maintenance throughout the dosing interval.

General Benefit: Why Are These Two Ingredients Combined?

The general purpose of Centyl K lies in its ability to achieve two simultaneous goals: Fluid and Salt Reduction and compensatory Potassium Balance Maintenance. By increasing the excretion of excess salt and water, the medicine helps manage elevated fluid volume.

This synergistic combination is critical because the diuretic's action is associated with potassium loss. Therefore, the inclusion of Potassium Chloride is integral to the product’s design. This dual function provides the core benefit of managing fluid balance without causing significant depletion of the essential electrolyte, supporting overall stability during long-term therapy.

Regulatory References

NIH RxNav: Bendroflumethiazide and Potassium Chloride

What side effects are possible with Centyl K?

Possible Side Effects and Safety Information

The safety profile of Centyl K (Bendroflumethiazide and Potassium Chloride) is formally structured by government regulatory documents, detailing potential adverse reactions classified by frequency and affected body systems. These classifications reflect how official sources organize and communicate the medicine’s risk profile, strictly excluding patient advice or usage instructions.

Frequency-Classified Adverse Reactions

The regulatory label categorizes side effects into frequency bands based on clinical data:

Classification	Examples of Officially Listed Effects
Common	Dizziness, headache, and fatigue (weakness).
Uncommon	Blurred vision, low blood pressure (hypotension), and palpitations.
Not Known	Electrolyte imbalances (e.g., hypokalaemia, hypercalcaemia, hyponatraemia), acid-base disturbance, and gastrointestinal upset.

Serious Adverse Reactions and Safety Constraints

The medicine is associated with risks that are explicitly documented in regulatory warnings. These include the potential for life-threatening hyperkalaemia (dangerously high potassium) and the risk of gastrointestinal ulceration or obstruction related to the solid, modified-release tablet design. Use is strictly limited by contraindications, which prohibit the medicine’s use in conditions such as severe renal or hepatic insufficiency, Addison's disease, or established gastrointestinal obstruction or ulceration. The diuretic component also presents a risk of electrolyte imbalance, which is a known pattern associated with this class of medicine. Additionally, the label requires caution and monitoring for specific groups, including elderly patients and those with a predisposition to diabetes mellitus or underlying cardiac disease.

Overdose and Emergency Response

Centyl K Overdose and When to Seek Help

The official regulatory profile for Centyl K (Bendroflumethiazide and Potassium Chloride) overdose describes severe physiological disturbances resulting from excessive diuretic activity and mineral loading.

Domain	Documented Manifestation / Action
Overdose Manifestations	Symptoms include profound Hypovolemia (reduced blood volume) and Hypotension, often accompanied by severe electrolyte disturbances like Hyponatraemia, dizziness, weakness, vomiting, and mental confusion.
Life-Threatening Outcomes	The primary critical risk involves Hyperkalaemia (potassium excess) from the Potassium Chloride component, which can precipitate severe Cardiac Arrhythmias and potentially Cardiac Arrest. Central Nervous System depression, leading to Seizures or Coma, is also a documented risk.
High-Risk Population	Elderly patients are specifically noted in official documentation as being at higher risk of complications, including thrombosis and embolism, secondary to acute blood-volume reduction.

Mandatory Emergency Intervention

Regulatory guidance explicitly requires that any suspected overdose prompt a patient to seek immediate medical help right away. Immediate attention is mandated upon the development of cardiac rhythm changes or documented severe hyperkalaemia (potassium concentration above 6.5 mmol/litre). Management is defined as symptomatic and supportive treatment, focused on fluid and electrolyte replacement. Interventions involve continuous ECG monitoring and the use of specific procedures, such as intravenous Calcium Gluconate or Insulin/Glucose infusions, for documented life-threatening hyperkalaemia.

Therapeutic Uses of Centyl K

What Centyl K Treats: Main Uses and Benefits

Centyl K is generally used to address symptom clusters that may become intense or disruptive, specifically in the domains of cardiovascular and fluid regulation. The medication is commonly applied in clinical settings that involve heightened systemic burden for the sustained management of essential hypertension and assisting with the symptomatic discomfort of oedema (fluid retention).

This support is considered relevant within the therapeutic plan for chronic conditions, including those related to heart failure or specific hepatic/renal disorders. The medication assists with managing symptoms related to physical discomfort, such as visible swelling in the legs and ankles, and symptoms related to heightened physiological activity, such as chronically high blood pressure.

The inclusion of Potassium Chloride supports electrolyte balance maintenance, which may assist with maintaining functional stability and is applied in addressing symptoms related to systemic imbalance that may accompany diuretic use. This provides support that helps ease the overall symptom burden during symptomatic phases.

Quick Fact: Therapeutic Support for Fluid and Pressure
Therapeutic Focus	Assistance with fluid reduction and support for blood pressure management.
Symptom Category Eased	Oedema (swelling) and symptoms of Potassium Depletion.
Relevant Scenario	Applied in scenarios requiring long-term management of chronic conditions.

Regulatory References

Summary of Product Characteristics from the Irish Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Centyl K — Official Regulatory Information

Eligibility Scope

Classification	Regulatory Status
Populations for whom use is allowed	Adult patients [HPRA SmPC]
Populations for whom use is not recommended	Women who are pregnant or breastfeeding [HPRA SmPC]
Populations for whom use is contraindicated	Patients with known hypersensitivity to the drug or sulfonamide-derived drugs, Addison’s disease, anuria, severe renal impairment, severe hepatic impairment, or pre-existing hyperkalaemia [HPRA SmPC]

Age-Related Eligibility Rules

Age Group	Regulatory Status
Paediatric Population	Use is contraindicated or not recommended in children and adolescents (under 18 years of age) because safety and efficacy have not been established [HPRA SmPC]
Older Adults	Use is generally allowed but requires caution due to increased risk of electrolyte imbalance, necessitating careful monitoring of serum potassium levels [HPRA SmPC]

Eligibility-Related Restrictions

Centyl K is contraindicated in patients receiving concomitant treatment with other potassium-sparing diuretics (e.g., amiloride, triamterene). Use also requires caution in patients with specific conditions, including mild or moderate renal or hepatic impairment, potential obstruction of the urinary tract, active or history of gout, Diabetes Mellitus, and Systemic Lupus Erythematosus [HPRA SmPC].

Connection to the Overall Eligibility Profile

The regulatory documents strictly define who can and cannot use the medicine by prohibiting use in populations with pre-existing conditions that pose a risk of severe electrolyte imbalance or organ failure. Use is specifically contraindicated in the pediatric population and not recommended during pregnancy or lactation due to lack of established safety, confining its use to the monitored adult population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Centyl K (Bendroflumethiazide and Potassium Chloride) that require attention and, in certain cases, strictly prohibit co-administration.

Interaction-Related Restrictions

Classification	Interacting Substance/Class	Official Interaction Statement
Contraindicated Combination	Potassium-sparing diuretics (e.g., Spironolactone)	Co-administration is formally prohibited due to the high risk of severe Hyperkalaemia (abnormally high potassium levels).
Exposure Modification	Lithium	Reduces Lithium's renal clearance, leading to elevated plasma concentration and increased risk of Lithium toxicity.
Absorption Interference	Bile-acid binding resins (e.g., Cholestyramine)	Formally documented to reduce the oral absorption of Bendroflumethiazide, potentially resulting in decreased systemic exposure.

Pharmacodynamic Effects and Monitoring

Co-administration with other Antihypertensives (e.g., ACE Inhibitors) may result in an enhanced hypotensive effect. The risk of cardiotoxicity is increased with Antiarrhythmics and Digitalis Glycosides due to the potential for diuretic-induced hypokalaemia. Non-steroidal Anti-inflammatory Drugs (NSAIDs) may antagonize the diuretic and blood pressure-lowering effects of the medicine. The label specifies that the effects of Antidiabetics may be reduced, and their dose may require adjustment. Alcohol may potentiate orthostatic hypotension, and supplements containing Calcium Salts or Vitamin D increase the risk of Hypercalcaemia.

Mechanism of Action

How Centyl K Works: Mechanism of Action

Centyl K's mechanism is defined by the complementary actions of its two components: the diuretic bendroflumethiazide and the supplement potassium chloride.

Targeting Renal Salt Transport and Fluid Volume

Bendroflumethiazide acts primarily as a reversible inhibitor of the Sodium-Chloride Cotransporter (NCC) in the kidney's distal convoluted tubules. By blocking the NCC, the molecule prevents the reabsorption of sodium and chloride from the renal filtrate back into the bloodstream. This inhibition initiates a mechanistic cascade, leading to increased water excretion (diuresis) and a subsequent reduction in total extracellular fluid volume.

Modulating Systemic Vascular Tone and Electrolyte Balance

The sustained reduction in fluid volume, combined with an effect on ion concentrations within vascular smooth muscle cells, modifies systemic vascular resistance. This physiological change promotes the long-term relaxation and widening of peripheral blood vessels. The second component, potassium chloride, provides substrate replenishment to counteract the potassium loss that is an intrinsic consequence of the diuretic's mechanism, which is required for the maintenance of serum potassium concentration.

Dosage and Administration Information

How to Use Centyl K

Centyl K is a modified-release film-coated oral tablet and must be administered exclusively by mouth as directed by the prescribing information. The use of this fixed-dose combination product is governed by a defined schedule and specific intake conditions that ensure the controlled delivery of both Bendroflumethiazide and Potassium Chloride.

Official Dosing Regimens

The total daily amount is typically administered as a single dose, once daily. The standard adult dosing range applies to older adults as well, but no official dosing is provided for pediatric patients.

Indication	Starting Dosage (Tablets once daily)	Maintenance Dosage (Tablets once daily)
Hypertension	1 -- 2 tablets	1 -- 2 tablets
Oedema (Fluid retention)	1 -- 4 tablets	1 -- 2 tablets

For oedema, treatment generally involves an initial, higher amount, which is then reduced to the lowest effective dose for long-term management once the desired fluid balance is achieved.

Administration Requirements

For proper administration, the tablets should be taken with or immediately following food to help minimize potential gastric irritation associated with the potassium component. The dose should be taken with at least a full glass of water or other fluid. To maintain the intended modified-release characteristics and ensure a proper rate of absorption, the tablet must be swallowed whole and should not be crushed, broken, or chewed. Administration is usually recommended in the morning to avoid potential disruptions to sleep from increased nighttime urination.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Centyl K

Centyl K, a fixed-dose combination of a diuretic and potassium, has been studied in research exploring two key areas: the context of high blood pressure and the context of fluid retention. The available evidence includes randomized controlled trials (RCTs) and long-term observational data specific to the drug class.

Evidence for Use in Managing Essential Hypertension

Research was observed in the context of essential hypertension, which is chronically high blood pressure without a clear underlying cause.

What researchers studied The evidence base for this context includes data from Randomized Controlled Trials (RCTs), many of which were double-blind. These studies explored the patterns measured in blood pressure, often comparing the medication against placebo or other standard treatments. Researchers also monitored outcomes related to systemic imbalance, such as levels of Serum Potassium, blood glucose, and serum urate, as the combination was studied to explore patterns related to electrolyte shifts caused by the diuretic component. The populations observed in these studies were primarily adults with mild to moderate high blood pressure, with some research including subsets of the elderly (≥ 70 years old).

What the studies reported (neutral summary) Trials reported measurements of changes in both systolic and diastolic blood pressure across treatment groups over intermediate follow-up periods, typically lasting several months. Findings from these trials indicate patterns related to the maintenance of blood pressure. The research describes patterns related to Serum Potassium levels when the diuretic component was combined with Potassium Chloride during diuretic therapy. Reported outcomes were short-term and focused on physiological changes measured during the study period, not long-term health events.

Evidence for Use in Managing Oedema (Fluid Retention)

Centyl K was evaluated in research settings exploring fluid volume patterns. The evidence is derived from a long history of clinical practice and research on the thiazide diuretic class.

What researchers studied Evidence for oedema (fluid retention or visible swelling) is generally derived from a combination of established clinical experience and non-comparative clinical data. These studies and observations monitored outcomes related to physical discomfort, such as the overall reduction of excess fluid volume and associated swelling. The patient populations were studied for fluid retention linked to specific chronic conditions, including congestive heart failure and hepatic cirrhosis.

What the studies reported (neutral summary) Clinical observation reported changes in fluid accumulation in the body for patients taking the medication. Research explores the inclusion of the Potassium Chloride component, showing that it was associated with patterns related to electrolyte levels, a pattern studied in the context of addressing fluid imbalances with a diuretic. These findings describe group patterns observed in patients requiring both short-term stabilization of fluid volume and long-term maintenance.

Long-Term Evidence and Durability of Study Findings

Research has also explored the duration of the medication's study period and the extent of long-term data available.

The primary RCTs examining effectiveness were conducted over limited follow-up durations, typically up to six months, focusing on immediate changes in blood pressure and physiological markers. While long-term effects are not fully established by Centyl K-specific trials, studies monitoring the diuretic drug class contribute to the broader evidence landscape regarding sustained use in chronic conditions. However, limited information for long-term outcomes means that the durability of the studied response and the full profile of metabolic stability beyond intermediate periods is not fully established in the published literature for the combination product itself.

Evidence in Specific Patient Populations

The research base has been studied for its application in certain patient groups who frequently require fluid volume monitoring or hypertension treatment.

Studies was observed in specific patient sub-groups, such as older adults with high blood pressure. Research also describes the use of the diuretic component in patients with co-existing conditions like heart failure or hepatic disorders, as these are conditions where fluid volume changes are common. Findings describe group patterns in these specific populations, though subgroup findings are uncertain when comparing detailed outcomes across all possible variations of comorbidities or age.

Research Gaps and Unanswered Questions

Even with the existing research, there are areas where evidence remains limited or where further study is needed, as noted by scientific reviews.

Comparative evidence is lacking for the specific Centyl K combination when weighed against all other possible treatment strategies for oedema or hypertension.
Sample sizes were modest in some of the smaller, non-comparative studies, meaning that results apply only to the populations studied and research does not determine whether an individual will respond similarly.
There is limited information on the long-term impact of Centyl K on major clinical outcomes like cardiovascular morbidity and mortality, which is a key endpoint for hypertension treatment.
Some trials were not specifically designed to track subjective outcomes, meaning evidence quality varies across studies for patient-reported outcomes describing perceived discomfort.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Centyl K (FAQ)

Q: Can Centyl K affect blood sugar levels?

Official documents indicate that Centyl K requires caution in adult patients who have a predisposition to Diabetes Mellitus. Clinical studies, according to research summaries, included blood glucose among the physiological markers that were monitored. This monitoring is related to the possibility of metabolic changes associated with the drug class.

Q: Does Centyl K cause muscle cramps or weakness?

According to the official product information, generalized fatigue (weakness) is listed as a Common side effect. However, muscle cramps are not explicitly named among the most frequently classified reactions in the official safety profile. Patients may refer to the full 'Possible side effects' section for a complete list of adverse reactions described in regulatory sources.

Q: Are there any foods or dietary components that interact with Centyl K?

Regulatory documents specify that supplements containing Calcium Salts or Vitamin D can increase the risk of hypercalcaemia, and their co-administration should be noted. Official administration instructions describe that the tablet should be taken with or immediately following food to help minimize potential irritation to the stomach caused by the potassium component.

Q: Is it safe to use potassium supplements while taking Centyl K?

The official eligibility map states that the medicine is strictly contraindicated (prohibited) in patients with pre-existing Hyperkalaemia, which is dangerously high potassium. Due to the high risk of severe potassium imbalance, co-administration with other potassium-sparing diuretics is also prohibited. These restrictions indicate the critical nature of managing total potassium intake while using this medication.

Q: Does Centyl K affect kidney function over time? (Informational)

Use is contraindicated in patients with severe renal impairment due to the risk of severe side effects. The drug's mechanism is defined by its action in the kidney's distal convoluted tubules. Official labeling specifies that caution is required in patients with existing kidney issues, necessitating monitoring.

Q: Is Centyl K described as having a risk of dehydration?

The medicine's core mechanism involves increasing water excretion, which results in a reduction of total fluid volume (diuresis). The official safety information lists low blood pressure (hypotension) as an Uncommon effect, which is a physiological pattern consistent with significant fluid loss.

Q: What kind of lab tests are typically recommended while taking Centyl K?

Official warnings require careful monitoring of serum potassium levels for specific populations, such as older adults, due to the risk of electrolyte imbalance. Research studies associated with the medicine have also monitored other metabolic markers, including blood glucose and serum urate. This type of monitoring is indicated for supporting stability during therapy.

Q: Can Centyl K cause stomach irritation or nausea?

Official documentation lists gastrointestinal upset (with a frequency of Not Known) and specifically warns of the potential for gastrointestinal ulceration or obstruction. Official instructions for administration describe that the tablet should be taken with or immediately following food to help minimize potential gastric irritation from the modified-release design.

Q: Where can a patient find the official patient information leaflet for Centyl K?

The official Patient Information Leaflet (PIL) or Medication Guide is published by government drug agencies, such as the MHRA / GOV.UK or the FDA / DailyMed. These documents are usually hosted on the agency's official website and provide the necessary patient information published by the regulator.

How should Centyl K be stored and disposed of?

The storage and disposal of Centyl K (bendroflumethiazide and potassium chloride) tablets are defined by official government labeling to ensure product stability and safety compliance.

Storage Requirements

Storage Condition	Official Requirement
Temperature Range	Store below 30 C.
Protection	Keep the container tightly closed in order to protect from moisture.
Packaging	Keep the medicine in the original container.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Any unused Centyl K and associated waste material must be disposed of in accordance with local requirements.

Patients are instructed not to throw away any medicines via wastewater or general household waste. Disposal methods should follow established local drug take-back or collection procedures.

Centyl K